



News & Information

Pompey, France, November 4, 2011:

Novasep, a leading supplier of manufacturing solutions to the life sciences industry, continues to have positive and productive restructuring negotiations with holders (the "Ad Hoc Group of Noteholders") of a majority in aggregate principal amount of Novasep's high yield notes due 2016 (the "Notes") issued pursuant to the Indenture dated as of December, 23 2009 (the "Indenture"), aimed at right-sizing Novasep's capital structure and providing Novasep with the required flexibility to capture future growth opportunities.

Within this framework, Novasep announces that an agreement was executed on October 28, 2011, whereby, among other things, the Ad Hoc Group of Noteholders agreed, on the terms and conditions provided therein, to waive certain Events of Default under the Indenture resulting solely from Novasep's commencement of a conciliation proceeding under Articles L.611-4 et seq. of the French Commercial Code. The conciliation proceeding results from restructuring negotiations conducted under the aegis of the mandataire ad hoc appointed on June 30, 2011 by the Tribunal de commerce de Nancy.

About Novasep: www.novasep.com

Novasep develops markets and operates innovative technologies providing life science industries with safe and cost-effective production of active molecules. The global manufacturing solutions offered by Novasep include process development services; purification equipment and systems; contract manufacturing services; and complex active molecules.

Contacts

NewCap.

Investor Relations

Axelle Vuillermet / Emmanuel Huynh

Tel.: +33 (0)1 44 71 94 93

Email: novasep@newcap.fr

***Next financial press release: Q3 2011 results,
November 30, 2011, after market close***